Anti-programmed cell death protein 1 (anti-PD-1) drugs were later approved, modulating the PD-1/PD-L1 complex and resulting in a greater anti-tumor response compared to ipilimumab monotherapy [9,11,12,18,19]. This evidence concerns the gene PDCD1 and neoplasm.